Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Heartflow, Inc. (Nasdaq: HTFL), a medical technology company that applies artificial intelligence to coronary computed tomography angiography (CTA) for non-invasive coronary artery disease detection and management. Investors can review the company’s periodic and current reports to understand its financial condition, risk factors, and key operational developments.
Heartflow’s Form 10-K annual reports and Form 10-Q quarterly reports describe its business as a commercial-stage provider of non-invasive CAD detection solutions built around the Heartflow One platform, including FFRCT Analysis and Plaque Analysis. These filings typically discuss revenue sources, geographic operations in regions such as the United States, the United Kingdom, Japan, and the rest of Europe, and the company’s status as an emerging growth company listed on the Nasdaq Global Select Market.
Form 8-K current reports offer more immediate updates on material events, such as financial results releases, participation in financing transactions, or changes to credit agreements. For example, Heartflow has used Form 8-K to furnish earnings press releases and to disclose the prepayment and termination of a prior credit agreement following its initial public offering.
Through this page, users can also locate proxy statements and executive compensation disclosures, as well as Form 4 insider transaction reports when applicable. Stock Titan enhances these filings with AI-powered summaries that explain complex sections, highlight important risk disclosures, and clarify how Heartflow’s CAD-focused health information services and AI technologies are reflected in its regulatory reporting. Real-time updates from the SEC’s EDGAR system ensure that new HTFL filings, including 10-Ks, 10-Qs, 8-Ks, and ownership reports, are available promptly for detailed review.
Heartflow, Inc. director Timothy C. Barabe exercised stock options and acquired 8,667 shares of common stock on March 11, 2026 at $2.22 per share. Following the transaction, he directly owns 179,521 common shares. The option grant continues to vest in monthly installments through July 1, 2027, subject to his continued service.
Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported mixed share activity. He sold 12,837 shares of common stock in an open-market transaction at $22.66 per share, executed under a pre-arranged Rule 10b5-1 trading plan.
Earlier, he acquired 2,631 shares at $16.15 per share as a grant under the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). After these transactions, he directly holds 581,450 shares of Heartflow common stock.
HTFL provided a Form 144 notice reporting proposed and recent sales of common stock by an affiliate. The filing shows a proposed sale related to a 06/25/2024 stock option exercise for 12,837 shares and discloses that John C. M. Farquhar sold 22,562 common shares on 02/10/2026 for $619,556.99.
Heartflow, Inc. director Julie A. Cullivan reported an open-market sale of 9,122 shares of common stock at $25.00 per share on March 5, 2026. After this transaction, she held 27,291 shares directly. The sale was executed under a previously adopted Rule 10b5-1 trading plan dated September 12, 2025.
Heartflow, Inc. Schedule 13G/A lists Wellington entities as beneficial owners of common stock with 11,921,247 shares reported and 14.00% of the class. The filing identifies shared voting power and shared dispositive power figures and lists related Wellington subsidiaries and investment advisers. The filing is signed and dated 03/06/2026.
HTFL disclosed a Form 144 notice reporting proposed sales of common stock by affiliated holders.
The excerpt lists a sale by Julie A. Cullivan of 8,000 common shares on 02/05/2026 for $218,560. It also shows Fidelity Brokerage Services LLC with an entry of 9,122 tied to a 12/17/2024 stock option exercise paid in cash.
Heartflow, Inc. director Timothy C. Barabe reported exercising stock options for 2,497 shares of common stock on February 17, 2026. The options were converted into common shares at $8.33 per share, increasing his directly held stake to 170,854 common shares. This was an option exercise (code M), not an open-market purchase.
Heartflow, Inc. Chief Medical Officer Campbell Rogers reported option exercises and share sales in HTFL stock. On February 12, 2026, he exercised multiple stock options, converting them into common shares at exercise prices of $2.22 and $8.33 per share.
On the same date, he then sold 65,153 shares of common stock in open-market transactions at a weighted average price of $24.4883 per share, under a Rule 10b5-1 trading plan adopted on September 12, 2025. After these transactions, he held 76,034 shares directly, with additional indirect holdings reported in several family and personal trusts.
HTFL filed a Form 144/A notice for a planned sale of up to 8,000 shares of its common stock through Fidelity Brokerage Services LLC on or about February 5, 2026 on NASDAQ. The aggregate market value of the planned sale is listed as 218,560.00.
The seller acquired 6,849 shares on June 15, 2024 and 1,151 shares on December 17, 2024 through stock option exercises from the issuer, paying cash in each case. Shares outstanding were 85,158,719 at the time referenced.
An affiliate of HTFL has filed a Rule 144 notice to sell 65,153 shares of common stock through Fidelity on the NASDAQ, with an aggregate market value of 1,595,485.25. The issuer had 85,158,719 shares outstanding at the time of the notice.
The shares to be sold were acquired over several years via stock option exercises, restricted stock vesting, and a prior option grant, with acquisition dates ranging from 2018 to 2026. The seller certified they are not aware of any undisclosed material adverse information about the issuer.